Recognizing the uniqueness of each cancer, RGCC Onconomics Plus is a comprehensive test provided by RGCC. It comprises not one, not two, but three distinct assessments. Through this multi-faceted approach, it offers unparalleled insights into the individualized response of patients to specific treatments. More than 110+ chemotherapy drugs, 50 natural substances, and 80+ genes are tested to know the best treatment options that suit you.
Onconomics Plus
Whole peripheral blood sample, Tissue for CNS Primary tumors
15-25ml blood, minimum 400mg tissue
All Types
21 days
The primary reason to choose RGCC Onconomics Plus is to enhance treatment success rates and elevate the overall quality of life for cancer patients. By understanding each cancer intricately, it equips both physicians and patients with the tools needed to navigate treatment decisions with confidence and precision. This test is a combination of three tests RGCC Oncocount, RGCC Onconomics, and RGCC Onconomics Extracts.
RGCC Onconomics Plus begins with the isolation and enumeration of Circulating Tumor Cells (CTCs). It then proceeds to assess the chemo-sensitivity and chemo-resistance of specific anti-cancer drugs, targeted therapies, and natural treatments.
Monitoring changes in gene expression during treatment allows clinicians to assess treatment response and adjust therapeutic strategies accordingly. This real-time feedback helps optimize patient care and improve outcomes.
The Onconomics plus panel provides information about the following details.
CTC count: By measuring the number of CTCs, doctors can track how aggressive the cancer is and whether treatments are working effectively and monitoring the disease.
Chemosensitivity of anti-cancer drugs: Chemosensitivity testing allows for a personalized approach to cancer treatment, ensuring that patients receive the most effective chemotherapy drugs for their specific type of cancer. This can lead to better treatment outcomes and improved quality of life for cancer patients by avoiding side effects.
Epigenetic analysis: Gene expression provides insights into gene regulation, development, disease, and potential therapeutic targets.
Onconomics Plus test consists of three different tests to provide information on CTC count, chemotherapeutic agents, and natural treatments to tailor treatment plans for patients. The test ensures that the chosen therapies are as effective as possible for each patient’s unique cancer profile.
The test applies to all types of cancer and not just limited to the following.
The first step towards personalized cancer care is scheduling an appointment with us.
Upon booking the appointment, you get a consultation with our RGCC experts to assess your cancer status.
We guide you through the process of selecting the most effective tests for your specific cancer.
We deliver precise results that guide treatment decisions and enhance outcomes.
Our RGCC accredited experts are here to help you with their expertise and guide you in your fight against cancer.
The RGCC Onconomics Plus test is advised for patients who are planning or currently undergoing combinational treatment planning (Chemotherapy & Integrative approaches).
The Onconomics Plus panel is an incredibly empowering tool that patients and practitioners can use to find out exactly what types of treatment options can help each patient for personalized treatment approaches.
Our cutting edge diagnostics and personalised tests makes a meaningful difference in the fight against cancer.
Absolutely, tests can be performed while undergoing treatment to assess the effectiveness of the treatment against cancer.
RGCC Metastat is an effective test for identifying secondary tumors development and its potential location. It helps detect secondary tumors through analyzing Circulating Tumor Cells (CTCs) in the bloodstream. The test provides valuable insights into disease progression and metastasis.
Your blood sample undergoes processing in cutting-edge laboratories by scientists and technicians to deliver insights into your cancer cells.
Tests personalize treatment regimens by providing crucial information on drugs and therapies tailored to effectively target cancer cells.
Yes, all RGCC tests utilize blood samples. However, certain cancers, like glioblastoma and brain tumors, may require additional samples such as CSF or tissue. Otherwise, a peripheral blood sample alone is enough.
Circulating Tumor Cells (CTCs) are cancer cells that have detached from the primary tumor and circulate in the bloodstream. Cancer Stem Cells (CSCs) are a subpopulation of CTCs and both serve as biomarkers for cancer.
Yes, tests like aCGH can pinpoint the origin of an unknown primary tumor by analyzing genetic abnormalities present in tumor cells.
Tests like ChemoSNiP and CAMBISeq provide information on the body’s response to the drugs and sensitivity to immunotherapy.
Looking for comprehensive insights into your cancer? With RGCC Onconomics Plus, you can take control of your treatment journey with personalized and effective options tailored just for you. Choose RGCC Onconomics Plus and empower yourself with the knowledge to navigate your cancer journey confidently.
Offering personalized tests from RGCC, our mission is to improve treatment outcomes, enhance survival rates, and elevate overall quality of life for those affected by cancer.
Copyright 2024 © All Right Reserved.
Designed by Bee High Media
Dr. Bharat PatodiyaSenior Medical Oncologist, Hyderabad